Innovation news

12 Mar 2018

Horacio Moreno (Barcelona, 1971) recently joined IRB Barcelona’s Innovation Department as the new Entrepreneur in Residence. Launched in 2016, this position aims to foster an entrepreneurial culture in our scientific community by hosting an in-house expert in bio-entrepreneurship for a year. Horacio holds a PhD in Biochemistry and a Master’s in Business Administration. He has has more than 16 years’ experience as a business developer in the biopharma industry, including at companies such as Almirall, Gebro Pharma and Menarini. He currently works as a consultant in business development for biotech companies, and he is also involved in training and teaching programmes at IQS (Institut...

<p>Age-related hearing loss involves several environmental factors and genes. Image: CIBERER</p>
23 Feb 2018

It seems the amino acid transporter SLC7A8/SLC3A2 plays an important role in this disease.

The study was coordinated by Manuel Palacín from IRB Barcelona and Virginia Nunes from IDIBELL.

<p>The overexpression of the gene Serpent in the Drosophila wing causes permanent overgrowth and it is sufficient to promote tumour development. Image: Kyra Campbell, IRB Barcelona</p>
19 Feb 2018

In spite of the difference between the cell functions responsible for giving rise to a tumour and for the metastasis of this same tumour, studies at IRB Barcelona using the fly Drosophila melanogaster reveal that some genes can drive both phenomena.

<p>The image shows a metastatic colon tumour infiltrated by the immune system (brown) after combined treatment with the TGF-beta inhibitor and immunotherapy.  (Author: Daniele Tauriello, IRB Barcelona)</p>
14 Feb 2018

A team headed by ICREA researcher Eduard Batlle discovers that immune system-stimulating treatments combined with a TGF-beta inhibitor are effective against colon cancer.

The researchers developed a mouse model that mimics advanced human colon cancer. This model has allowed them to study the immune system response for the first time.

<p>Image: BIST</p>
17 Jan 2018

GenStorm (“An integrated approach to visualize and model the spatial conformation of genes at the nanoscale level”), led by Pablo Daniel Dans (IRB Barcelona) and Marie Victoire Neguembor (CRG) is one of this projects.

<p>Confocal microscopy shows co-localization of EXD2 (magenta) with the mitochondrial ribosome (yellow). DNA is stained to define the nucleus (cyan).</p>
16 Jan 2018

Published in Nature Cell Biology (NCB), the study shows that the EXD2 protein is critical for the mitochondria, the cell’s powerhouses, to produce energy.

This protein was previously thought to be located in the cell nucleus and to be involved in DNA repair.

The results contribute to our basic understanding of mitochondria and suggest that EXD2 could be important for fertility and represent a potential target for cancer therapy.

<p>Launch of "Crazy ABout Science". Image: Fundación Catalunya - La Pedrera</p>
15 Jan 2018

The programme seeks to stir young people’s interest in science by allowing them to get involved in real projects.

"Crazy About Biomedicine" is part of an initiative run by the Fundación Catalunya - La Pedrera.

<p>Attendants to the 100xciencia2 meeting on tech transfer and innovation (Photo: INA-CSIC-UMH)</p>
3 Nov 2017

This morning Alicante has started the 100xCiencia.2 meeting, which today and tomorrow brings together the vanguard of Spanish research: the Severo Ochoa and María de Maeztu centers of excellence.

The meeting was opened by Carmen Vela, Secretary of State for Research, Development and Innovation, and she highlighted the importance of approaching science and business.

<p>Roger Gomis, head of the Growth Control and Cancer Metastasis Lab and founder of Inbiomotion, a spin-off of IRB Barcelona and ICREA.</p>
31 Oct 2017

ICREA researcher Roger Gomis, head of the Growth Control and Cancer Metastasis Lab, has recently been awarded a 2016 "Knowledge Industry Grant" (Producte), by the Catalan Government’s Agency for Management of University and Research Grants, for the further development of a therapy for the treatment of breast cancer. His 18-month project, "Lipid targeting in breast cancer", aims to obtain a monoclonal antibody, based on a well-defined molecular target, that is suitable for patient treatment and to complete its pre-clinical development phase. 

24 Oct 2017

In an extensive article, the channel of science and technology news Néxt/VózPopuli relates how tycoons in Silicon valley are attempting to buy eternal youth.

Manuel Serrano, researcher at IRB Barcelona, and other experts on ageing consulted, consider that there is an investment “bubble” in the anti-aging research field. “It’s great that wealthy people believe that ageing is a condition that can be treated,” he says. “We are starting to get spectacular results in mice and I think there is a sufficient scientific basis for optimism. If I were rich I would also be investing in this,” he concludes.

Read the article here:...